Product Name: BCL10 Antibody [4F8E8H8]
Species Reactivity: Human
Tested Applications: ELISA, IHC, WB
Applications: IHC(P):Dilution 1:1,000 – 1:2,000IHC(F):Dilution 1:1,000 – 1:2,000Western blot:Dilution 1:2,000 – 1:5,000ELISA:Propose dilution 1:10,000.Determining optimal working dilutions by titration test.
User Note: Optimal dilutions for each application to be determined by the researcher.
Predicted Molecular Weight:
Immunogen: Ni-NTA purified recombinant human BCL-10 expressed in E. Coli strain BL21 (DE3).
Host Species: Mouse
Purification: Antibody is purified by protein A affinity chromatography.
Physical State:
CAS NO.: 40596-69-8
Product: Methoprene
Buffer:
Concentration:
Storage Conditions: BCL-10 monoclonal antibody can be stored at -20˚C, stable for one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Clonality: Monoclonal
Conjugate: Unconjugated
Alternate Names: CIPER, CLAP, CARD-containing molecule enhancing NF-kappa-B, Bcl-10, mE10, CIPER, c-E10, CARMEN
Accession NO.: O95999
Protein Ino: 20454813
Official Symbol: BCL10
Geneid: 8915
Background: B-cell CLL/lymphoma 10, also known as CLAP, Me10, CIPER, c-E10, CARMEN. Entrez Protein NP_003912. It is a protein containing a caspase recruitment domain (CARD). It plays an important role in apoptosis and activating NF-κB. The research suggested that it interacted with other CARD domain containing proteins including CARD9, 10, 11 and 14, which were thought to function as upstream regulators in NF-κB signaling. Bcl-10 is found to form a complex with MALT1 which encoded by another gene known to be translocated in MALT lymphoma. MALT1 and Bcl-10 are thought to synergize in the activation of NF-κB, and the deregulation of either of them may contribute to the same pathogenetic process that leads to the malignancy.
PubMed ID:http://aac.asm.org/content/53/12/4979.abstract
